tqh2722

mAbexperimental

Clinical trial activity

6 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
5
Phase 3
1
Phase 4
0

Earliest trial started Jun 30, 2022 (NCT05409326)

Timeline

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2023

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06760182Phase 2Mar 10, 2025Government of China
NCT06552520Phase 3Sep 30, 2024Government of China
NCT06439381Phase 2Jul 16, 2024Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
NCT06089278Phase 2Nov 30, 2023Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
NCT05970432Phase 2Jun 19, 2023Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
NCT05409326Phase 1Jun 30, 2022Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,LtdFor profit4422022
Government of ChinaGovernment2222024
2 organizations
Page 1 / 1